Bookmark

Add to MyYahoo RSS

Orexigen Therapeutics News

News on Orexigen Therapeutics (Ticker: OREX) continually updated from thousands of sources around the net.

8 hrs ago | AmericanBankingNews.com

Insider Buying: Michael Narachi Acquires 50,000 Shares of Orexigen Therapeutics Stock

Orexigen Therapeutics CEO Michael Narachi acquired 50,000 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was purchased at an average price of $4.78 per share, with a total value of $239,000.00.

Comment?

Related Topix: Biotech, Orexigen Therapeutics

Fri Sep 12, 2014

NBC San Diego

Orexigen's Contrave Approved by FDA

The U.S. Food and Drug Administration has approved a weight-loss drug developed by La Jolla-based Orexigen Therapeutics Inc. Orexigen is partnered with Japanese pharmaceutical giant, Takeda Pharmaceutical Company Ltd., to manage marketing and sales of the new drug, Contrave. Takeda has assigned 900 sales representatives to the launch.

Comment?

Related Topix: Food and Drug Administration, San Diego, CA, La-Jolla, CA, La Jolla Pharmaceutical, Biotech, Medicine, Healthcare Industry, Orexigen Therapeutics

Thu Sep 11, 2014

AmericanBankingNews.com

Orexigen Therapeutics Price Target Raised to $15.00

Wells Fargo & Co.' s price objective would indicate a potential upside of 154.24% from the stock's previous close.

Comment?

Related Topix: Biotech, Orexigen Therapeutics

Applied Clinical Trials

Takeda and Orexigen Announce FDA Approval of Contrave? (naltrexone...

Takeda and Orexigen Announce FDA Approval of Contrave? Extended-release Tablets for Chronic Weight Management Takeda and Orexigen Announce FDA Approval of Contrave Extended-release Tablets for Chronic Weight Management , Inc. and Orexigen Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater , or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Medicine, Alcoholism, Health, Biotech, Orexigen Therapeutics, Life, Food, Nutrition

Wed Sep 10, 2014

Windsor Beacon

FDA approves a third new weight-loss pill

For the third time in about two years, the Food and Drug Administration has approved a new weight-loss pill. Contrave got FDA approval Wednesday.

Comment?

Related Topix: Food and Drug Administration, Biotech, Orexigen Therapeutics

Sys-Con Media

Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014

The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

Comment?

Related Topix: Biotech, Orexigen Therapeutics

Journal Gazette

Weight-loss drug clears FDA hurdle

Novo Nordisk's drug, to be named Saxenda, helped 60 percent of patients studied lose at least 5 percent of their weight and 31 percent lose more than 10 percent, according to a report Tuesday by the U.S. Food and Drug Administration staff.

Comment?

Related Topix: Food and Drug Administration, Biotech, Novo Nordisk AS, Orexigen Therapeutics, Medicine, Healthcare Industry, Arena Pharmaceuticals

Thu Sep 04, 2014

AmericanBankingNews.com

Orexigen Therapeutics Research Coverage Started at Credit Suisse

The firm set an "outperform" rating and a $10.00 price target on the stock. Credit Suisse's target price indicates a potential upside of 71.82% from the stock's previous close.

Comment?

Related Topix: Biotech, Orexigen Therapeutics

Wed Sep 03, 2014

BioSpace

Orexigen Therapeutics, Inc. Expands NB32 Intellectual Property Portfolio With New U.S. Patent

NB32 is a fixed-dose combination of naltrexone sustained release and bupropion SR.

Comment?

Related Topix: Biotech, Orexigen Therapeutics, Patent / Trademark Law, Law, Healthcare Law, Food and Drug Administration, Marketing

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••